- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Diagnostic Imaging's A Look Ahead: Dec. 14, 2020, to Dec. 20, 2020
Here's what to expect this week on Diagnostic Imaging.
In this week’s preview, here are some highlights of what you can expect to see coming soon on Diagnostic Imaging:
In continuing end-of-year coverage, keep an eye out for a look back at CT throughout 2020. What were the biggest developments and changes during the year. The biggest focus over the past nine months has certainly been with COVID-19, but what else happened with the modality as the pandemic raged?
For additional end-of-year coverage, click here.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
RadXX announced their four award winners during RSNA – Trailblazer, Advocate, Rising Star, and Champion. Diagnostic Imaging spoke with each winner to find out not only what launched their interest in medical imaging informatics, but also what their visions were for the specialty going forward. Later this week, you can access a short video where they share their thoughts in their own words.
For more of the RadXX profiles, click here.
In the past 40 years, liver cancer diagnoses have tripled, and deaths have nearly doubled, making it a cancer to watch closely. Later this week, look for coverage of research that focuses on the use of ultrasound to impact liver tumors, potentially affecting overall treatment outcomes.
For additional liver cancer coverage, click here.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.
